Oral Medicine Unit, Department of Oral & Maxillofacial Surgery, Baruch Padeh Medical Center, Poria, and Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
Oral Medicine Unit, Department of Oral & Maxillofacial Surgery, Baruch Padeh Medical Center, Poria, Israel.
Immunotherapy. 2020 Aug;12(11):777-784. doi: 10.2217/imt-2019-0162. Epub 2020 Jul 2.
To report of severe chronic oral mucositis (OM) in two pembrolizumab-treated cancer patients. A retrospective chart review was performed. Inclusion/exclusion criteria detected patients that developed OM during pembrolizumab immunotherapy. In addition, we searched the literature for nonlichenoid OM in immunotherapy-treated cancer patients. Two male patients treated for anaplastic astrocytoma and lung adenocarcinoma were included. Extensive painful OM (grade 4) developed in both patients during the course of immunotherapy and the ulcerations remained >30 weeks (>16 weeks after stopping immunotherapy). Superficial mucocele appeared in one patient. In one patient, pain relief was achieved with photobiomodulation (low-level laser) therapy. OM induced by immunotherapy may be a major cause of suffering and eating difficulties. In most cases, the OM lasted for months even after the drug was stopped. There is a controversy regarding the beneficial effect of corticosteroids on OM in these patients.
报告 2 例接受派姆单抗治疗的癌症患者发生严重慢性口腔黏膜炎（OM）。进行了回顾性图表审查。纳入/排除标准检测到在派姆单抗免疫治疗期间发生 OM 的患者。此外，我们还在免疫治疗治疗的癌症患者的非苔藓样 OM 文献中进行了搜索。纳入了 2 名接受间变性星形细胞瘤和肺腺癌治疗的男性患者。在免疫治疗过程中，两名患者均发生广泛疼痛性 OM（4 级），且溃疡持续>30 周（免疫治疗停止后>16 周）。一名患者出现浅表黏液囊肿。一名患者接受低水平激光治疗（光生物调节）后疼痛缓解。免疫治疗引起的 OM 可能是导致患者痛苦和进食困难的主要原因。在大多数情况下，即使在停药后，OM 仍持续数月。对于这些患者，皮质类固醇对 OM 的有益作用存在争议。
